MannKind Corporation (MNKD)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 4
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, so no long is admissible despite the constructive chart (price 4.13 above sma20/sma50/sma200, ADX 28.6 rising, MACD positive); no breakout stop or pullback limit can be emitted while either override gate fails.
Company overview
MannKind Corporation is a biopharmaceutical company focused on developing and marketing respiratory-delivered treatments for endocrine system disorders and rare lung conditions in the U.S. Its main products include Afrezza, an inhaled insulin for diabetes, and Thyquidity for hypothyroidism. The company collaborates with United Therapeutics and NRx Pharmaceuticals on various projects.
Fundamental
weakMannKind shows fast revenue growth but faces negative cash flow, high debt, and equity dilution risks.
MannKind pairs fast revenue growth (roughly $413M trailing twelve months, +27% year to date) and 76% gross margins with widening 2026 losses, negative free cash flow and negative stockholders' equity. Cash and cash equivalents of $41.3M sit barely above a $40M minimum-liquidity covenant, the $325M secured term loan costs about 9.2% and pledges substantially all assets, and equity has been repeatedly issued to cover obligations. SEC filings disclose no going concern and no covenant breach, and analysts carry a $10-$11 target against a $4.13 share price — a real bull case resting on the Furoscix/ReadyFlow launch and a royalty stream that is 56-60% concentrated in one customer now developing a competing inhaler. Weak, cash-consumptive fundamentals with elevated risk.
Sentiment
weakSentiment is flat with no actionable catalysts, and retail sentiment remains indeterminate.
Dominant catalyst is the announced Q3-2026 print (2026-11-05) — total revenue +24% year over year and commercial product revenue +102%, but a $101.9M top line that missed consensus and a GAAP net loss, so the tape's reception is two-sided and the catalyst is direction-neutral, leaving no forward-dated driver inside the 30-day horizon. The sentiment delta is flat rather than improving (baseline polarity_score ≈ +0.205 on 8 scored items versus ≈ +0.21 on 4 in the scoring window), retail is indeterminate after a Reddit 403 block, and the Red-Flag Screen is clean — with only a trailing neutral catalyst and an empty forward calendar the setup is absent-to-weak, not mixed.
Technical
goodThe stock trades above key moving averages with rising ADX, but lacks a viable trade setup.
The chart itself is constructive but the trade is blocked by both override floors. Price 4.13 sits above sma20 3.62, sma50 3.57, sma200 3.65, ema9 4.00 and ema21 3.77 after a ~38% advance off the 2026-10-15 low of 3.00; ADX14 28.60 and rising (17.94 on 2026-11-02) confirms a real up-trend rather than a bounce, MACD 0.20/0.12/0.08 is positive and above signal, and RSI14 66.58 / Williams %R -14.29 show strong but not extreme momentum. Negatives: price is ~14% above its sma20 and stalling under the 4.24-4.29 highs set on 2026-11-10/11-12 on shrinking volume (1.69M shares on 2026-11-13 versus 3.3-4.1M earlier in the month), and the MACD histogram has contracted 0.11 -> 0.09 -> 0.08 over the last three sessions. Chart quality 4/5; no production entry because fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3.
You’re looking at 2026-11-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

